Treatment with a CD133 monoclonal antibody resulted in cell death in hepatoma LM3, HepG2, Hep3B and Huh-7 cells, especially under low glucose conditions (Chen et al., 2013a). Here, PROM1 is linked to hepatocellular carcinoma.